Advertisement
UK markets close in 2 hours 7 minutes

  • FTSE 100

    8,036.85
    +12.98 (+0.16%)
     

  • FTSE 250

    19,700.08
    +100.69 (+0.51%)
     

  • AIM

    752.94
    +3.76 (+0.50%)
     

  • GBP/EUR

    1.1616
    +0.0027 (+0.24%)
     

  • GBP/USD

    1.2391
    +0.0041 (+0.33%)
     

  • Bitcoin GBP

    53,353.93
    +37.62 (+0.07%)
     

  • CMC Crypto 200

    1,421.82
    +7.06 (+0.50%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    81.33
    -0.57 (-0.70%)
     

  • GOLD FUTURES

    2,325.30
    -21.10 (-0.90%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,064.10
    +203.30 (+1.14%)
     

  • CAC 40

    8,086.24
    +45.88 (+0.57%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Corneal Endothelial Dystrophy (CED) 11 Year Forecasts, 7MM Coverage, Key Cross Competition, Featuring Aerie Pharmaceuticals, Kowa Pharmaceuticals and Trefoil Therapeutics

Research and Markets
·4-min read

Dublin, April 06, 2021 (GLOBE NEWSWIRE) -- The "Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of Corneal Endothelial Dystrophy (CED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Scope of the Report

  • The report covers the descriptive overview of Corneal Endothelial Dystrophy (CED), explaining its causes, signs and symptoms, physiology, and currently available therapies

  • Comprehensive insight has been provided into the Corneal Endothelial Dystrophy (CED) epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Corneal Endothelial Dystrophy (CED) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of the Corneal Endothelial Dystrophy (CED) market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Corneal Endothelial Dystrophy (CED) market

Report Highlights

  • In the coming years, the market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market

  • The companies and academics are working to assess challenges and seek opportunities that could influence Corneal Endothelial Dystrophy (CED) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition

  • Major players are involved in developing therapies for Corneal Endothelial Dystrophy (CED). The launch of emerging therapies will significantly impact the Corneal Endothelial Dystrophy (CED) market

  • The in-depth analysis of the pipeline assets across different stages of development (Phase I/II, and II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

ADVERTISEMENT

Report Insights

  • Patient Population

  • Therapeutic Approaches

  • Corneal Endothelial Dystrophy (CED) Pipeline Analysis

  • Corneal Endothelial Dystrophy (CED) Market Size and Trends

  • Market Opportunities

  • Impact of upcoming Therapies

Report Key Strengths

  • 11 Years Forecast

  • 7MM Coverage

  • Corneal Endothelial Dystrophy (CED) Epidemiology Segmentation

  • Key Cross Competition

  • Highly Analyzed Market

  • Drugs Uptake

Key Questions

Market Insights:

  • What were the Corneal Endothelial Dystrophy (CED) Market share (%) distribution in 2017 and how it would look like in 2030?

  • What would be the Corneal Endothelial Dystrophy (CED) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?

  • What are the key findings of the market across 7MM and which country will have the largest Corneal Endothelial Dystrophy (CED) market Size during the forecast period (2017-2030)?

  • At what CAGR, the Corneal Endothelial Dystrophy (CED) market is expected to grow in 7MM during the forecast period (2017-2030)?

  • What would be the Corneal Endothelial Dystrophy (CED) market outlook across the 7MM during the forecast period (2017-2030)?

  • What would be the Corneal Endothelial Dystrophy (CED) market growth till 2030, and what will be the resultant market Size in the year 2030?

  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Corneal Endothelial Dystrophy (CED) along with the approved therapy?

  • What are the current treatment guidelines for the treatment of Corneal Endothelial Dystrophy (CED) in the USA, Europe, and Japan?

  • What are the Corneal Endothelial Dystrophy (CED) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?

  • How many companies are developing therapies for the treatment of Corneal Endothelial Dystrophy (CED)?

  • How many therapies are developed by each company for the treatment of Corneal Endothelial Dystrophy (CED)?

  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Corneal Endothelial Dystrophy (CED)?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Corneal Endothelial Dystrophy (CED) therapies?

  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for CED and their status?

  • What are the key designations that have been granted for the emerging therapies for Corneal Endothelial Dystrophy (CED)?

  • What are the global historical and forecasted market of CED?


Companies Mentioned

  • Aerie Pharmaceuticals

  • Kowa Pharmaceuticals

  • Trefoil Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/h2rzwq

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900